ViewRay Systems, Inc. designs, manufactures, and markets magnetic resonance imaging radiation therapy system in the United States and internationally. The company offers MRIdian A3i, an MRI-guided radiation therapy system that provides real-time 3D tissue tracking and automated beam control. Its product is used for the treatment of pancreas, prostate, lung, liver, breast, and oligometastatic cancers. The company was founded in 2004 and is headquartered in Oakwood, Ohio. On July 16, 2023, ViewRay, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
0 transactions — 0 buys and 0 sales reported by ViewRay Systems, Inc. executives.
1 institutional funds report a position on VRAYQ in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of VRAYQ on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year